GLAD-PC Part II – Treatment & Ongoing Management

Scope & Objectives

• Update to GLAD-PC (Guidelines for Adolescent Depression in Primary Care)

  • Part II focuses on treatment and ongoing management for youth aged $10\text{–}21\ \text{yr}$ in primary-care (PC) settings.

  • Complements Part I (practice preparation, identification, assessment, diagnosis, initial management).

  • Developed with evidence + expert consensus, youth & family input; strength of each recommendation graded.

  • Aims

  • Equip PC clinicians to screen, treat, monitor, & comanage depression amid shortage of mental-health (MH) specialists.

  • Provide algorithm for active monitoring, evidence-based meds/psychotherapy, side-effect surveillance, collaborative care, outcome tracking, & next-step guidance for partial/no response.

Epidemiology & Background

• Point prevalence of adolescent depression

  • Community: up to $9\%$ currently; $\approx 20\%$ lifetime.

  • PC clinics: up to $28\%$.

• Under-identification & undertreatment common in PC.

• Only small proportion receive specialist MH care → PC is de-facto MH clinic.

• PC clinicians report inadequate training, support, reimbursement.

• Existing specialty guidelines (e.g., AACAP) not directly transferable to PC → necessity for GLAD-PC (2007, 2018 update).

Integrative / Collaborative Care Models

• Movement from solo practice → team-based, chronic-care paradigms ("integrative care").

• Shared elements

  • Multidisciplinary team incl. patient & family, ready access to MH expertise.

  • Systematic identification & tracking of target population.

  • Structured symptom-management protocols & regular follow-ups.

  • Enhanced communication, reduced fragmentation, support for self-management.

  • Case management, performance metrics, quality-improvement loops.

• Key RCT evidence (only 3 trials)

  1. Asarnow et al 2005 – Quality-improvement intervention → ↑ therapy uptake, ↓ symptoms, ↑ QoL.

  2. Clarke et al 2005 – 4-session CBT adjunct to SSRI in collaborative care → small additive benefit.

  3. Richardson et al 2014 – Teens chose med, brief CBT, or both within integrative model → better 12-mo response/remission & cost-effective.

• Unknown "active ingredients"; resource-intensive; guidance scarce for low-resource practices.

Antidepressant Treatment Evidence

• Updated review: 27 RCTs (fluoxetine, sertraline, citalopram, paroxetine, escitalopram, duloxetine, venlafaxine).

  • Older classes (TCAs, MAOIs) excluded (poor efficacy / not in FDA dataset).

• Meta-analysis (Bridge et al 2005): Number-needed-to-treat : number-needed-to-harm = 6:1 (benefit outweighs risk).

• Individual trial response rates (CGI-Improvement)

  • Medications: $47\text{–}69\%$ vs placebo $33\text{–}57\%$ (see "Tables & Key Numbers").

  • Fluoxetine still has most robust evidence; FDA-approved for $\ge 8\ \text{yr}$.

• TADS study (439 pts): Fluoxetine + CBT > fluoxetine alone > CBT alone ≈ placebo at 12 wk; combination yields faster response.

• TORDIA (SSRI-resistant, 334 pts): Switch + CBT (to another SSRI or venlafaxine) ↑ response (≈$55\%$) vs med switch alone (≈$41\%$).

• Adverse events

  • Common: nausea, headache, activation; higher discontinuation with duloxetine, venlafaxine, paroxetine.

  • Suicidality: FDA 2004 black-box; pooled risk $4\%$ (drug) vs $2\%$ (placebo). Highest with paroxetine & venlafaxine.

  • Epidemiology paradox: ↓ suicide rates where SSRI prescribing ↑; toxicology of youth suicides rarely shows antidepressants.

Psychotherapy Evidence

Cognitive Behavioral Therapy (CBT)

• Multiple meta-analyses show efficacy; ongoing trials up to $21\ \text{yr}$.

• TADS: 15 sessions/12 wk CBT response $43\%$ (not > placebo, likely due to severe sample & non-specific medication visits).

• Computerized CBT (SPARX, Project "CATCH-IT", etc.) effective incl. PC settings.

Interpersonal Psychotherapy for Adolescents (IPT-A)

• Fewer studies but positive:

  • Tang et al 2009 (school): IPT-A > TAU for depression, suicidality, hopelessness.

  • Baseline interpersonal problems predict greater IPT-A benefit (Gunlicks-Stoessel 2010).

  • Skills-training variant superior to supportive counseling over 8 wk.

Combination Therapy

• Generally superior to single modality, esp. moderate-to-severe depression & SSRI-resistant cases.

Treatment Recommendations (Evidence Grade / Consensus Strength)

• R1: Organize PC setting for integrated/collaborative care (grade 4, very strong).

• R2: For mild depression → 6–8 wk active support & monitoring before meds/therapy (grade 3, very strong).

• R3: For moderate/severe or complicating factors → consult/comanage with MH; delineate roles; engage family (grade 5, strong).

• R4: Offer scientifically proven treatments (CBT, IPT-A, SSRIs) tailored to severity, patient preference, comorbidity (grade 1, very strong).

Ongoing Management & Follow-up Recommendations

• Tracking: Regularly assess symptoms + functioning (home, school, peers) & suicidal risk (grade 4, very strong).

  • Ideal first follow-up: within 1 week of treatment start (phone or face-to-face acceptable).

• Monitoring of adverse events (esp. suicidality, activation, mania) mandatory during SSRI therapy (grade 3, very strong).

  • FDA wording: observe closely during first months & dose changes.

• Timeframes

  • Re-assess diagnosis & treatment if no improvement by 6–8 wk; consider MH consult (grade 4, very strong).

  • Partial responders: explore adherence, comorbidity, stressors; add/switch modality; seek MH input (grade 4, very strong).

  • Maintenance: continue meds 6–12 mo after remission; monitor monthly. First relapse risk highest $8\text{–}12\ \text{wk}$ post-discontinuation.

  • Recurrent depression: monitor up to $2\ \text{yr}$.

• Shared-care: PC should stay involved after referral; collaborative/shared models show better outcomes (grade 1, very strong).

Medication Dosing & Titration (SSRIs)

• General principles

  • Start low, titrate every $1\text{–}2\ \text{wk}$ as tolerated.

  • Max doses often lower than adult ranges.

  • Taper gradually to avoid withdrawal.

• Typical schedule (qd = once daily)

  • Fluoxetine: start $10\,\text{mg}$; ↑ by $10\text{–}20$; usual $20\,\text{mg}$; max $60\,\text{mg}$.

  • Sertraline: start $25\,\text{mg}$; ↑ by $12.5\text{–}25$; usual $50\,\text{mg}$; max $200\,\text{mg}$.

  • Citalopram: start $10$; ↑ by $10$; usual $20$; max $60$.

  • Escitalopram: start $10$; ↑ by $5$; usual $10$; max $20$.

  • Paroxetine: start $10$; usual $20$; caution—higher suicidality & withdrawal, not recommended for initiation in PC.

  • All SSRIs contraindicated with MAOIs.

CBT vs IPT-A – Core Components

• CBT: behavioral activation, cognitive restructuring, problem-solving, assertiveness training; may include parent sessions.

• IPT-A: addresses interpersonal problem area, communication patterns, interpersonal problem-solving; parents involved in specific phases.

Ethical, Practical, & Policy Implications

• Need for system changes: training PC clinicians in MH, reimbursement structures, crisis linkages.

• PC providers must discuss risks/benefits openly; use shared decision-making.

• Equity: integrative models resource-heavy → risk widening care gap; guideline calls for research on feasibility & sustainability.

• Black-box warning necessitates balancing caution with evidence of benefit & public-health suicide data.

Implementation Barriers & Future Directions

• Evidence gaps: augmenting agents, subthreshold depression, dismantling integrative models, long-term outcomes.

• Guidelines alone insufficient → require dissemination strategies, QI initiatives, Toolkit (www.gladpc.org).

• Ongoing evaluation of child psychiatry access programs (e.g., Project TEACH, MCPAP) for scalability.

Tables & Key Numbers (Quick Reference)

• Prevalence in PC: $\le 28\%$.

• Response rates (CGI Improvement)

  • Fluoxetine $56\%$ vs placebo $33\%$; P =.02

  • Paroxetine $66\%$ vs $48\%$; P =.02

  • Sertraline $63\%$ vs $53\%$; P =.05

• Suicidality risk: $\text{SSRI}=4\%$ vs $\text{placebo}=2\%$ (doubling).

• TORDIA partial response with CBT + med switch $54.8\%$ (CI $47\text{–}62\%$) vs switch alone $40.5\%$.

Key Take-Home Messages

• Start with active monitoring for mild cases; escalate if no improvement.

• For moderate–severe depression, offer CBT/IPT-A and/or an SSRI, ideally in combination, plus close monitoring.

• Fluoxetine remains first-line SSRI; monitor for activation & suicidality.

• Implement integrated or collaborative care whenever feasible; maintain PC involvement even after referral.

• Track both symptoms & functioning; adjust plan by week 6-8 if inadequate response.

• Maintain treatment 6–12 mo beyond remission, monitor $\ge1\ \text{yr}$, longer for recurrent cases.

• Utilize GLAD-PC Toolkit for scripts, handouts, monitoring scales, QI tools.

Scope & Objectives

• Update to GLAD-PC (Guidelines for Adolescent Depression in Primary Care)- Part II focuses on treatment and ongoing management for youth aged $10 ext{–}21 ext{ yr}$ in primary-care (PC) settings.

  • Complements Part I (practice preparation, identification, assessment, diagnosis, initial management), providing a comprehensive guide.

  • Developed with a rigorous approach combining evidence synthesis, expert consensus, and invaluable input from youth and their families to ensure practical relevance and patient-centeredness; the strength of each recommendation is explicitly graded based on the quality of evidence.

  • Aims:

    • To equip PC clinicians with the necessary tools and knowledge to effectively screen, treat, monitor, and comanage depression in adolescents, especially critical given the significant shortage of mental-health (MH) specialists.

    • To provide a clear, actionable algorithm that guides clinicians through active monitoring, selection of evidence-based medications and psychotherapy, diligent side-effect surveillance, principles of collaborative care, systematic outcome tracking, and clear next-step guidance for situations involving partial or no therapeutic response.

Epidemiology & Background

• Point prevalence of adolescent depression:

  • In the community: up to $9\%$ currently affected; approximately $20\%$ experiencing it over their lifetime, highlighting a significant public health burden.

  • In PC clinics: reported prevalence can be as high as $28\%$ due to this setting often being the first point of contact for health concerns, including mental health.

• Under-identification & undertreatment are pervasive issues in PC settings, often stemming from lack of training, time constraints, and perceived stigma.

• Only a small proportion of adolescents receive specialized MH care, leading to PC clinics effectively becoming the de-facto MH clinic for many youth, underscoring the critical need for PC-focused guidelines.

• PC clinicians frequently report inadequate training, systemic support, and appropriate reimbursement for mental health services, creating significant barriers to effective care.

• Existing specialty guidelines (e.g., American Academy of Child and Adolescent Psychiatry - AACAP) are comprehensive but often not directly transferable or practical for the busy PC environment, thus necessitating the development of the GLAD-PC guidelines (originally published in 2007, with a key update in 2018).

Integrative / Collaborative Care Models

• A crucial movement from traditional solo practice to team-based, chronic-care paradigms, commonly referred to as "integrative care," which emphasizes a holistic and coordinated approach.

• Shared elements of successful models:

  • Formation of a multidisciplinary team, crucially including the patient and family as active participants, alongside ready access to mental health expertise (e.g., through consultation, co-location, or tele-psychiatry).

  • Systematic identification & tracking of the target population using standardized screening tools to ensure no one falls through the cracks.

  • Implementation of structured symptom-management protocols and regular follow-ups to monitor progress and adjust treatment as needed.

  • Enhanced communication channels and reduced fragmentation of care across different providers and settings, supporting a seamless patient journey.

  • Provision of support for patient self-management, empowering adolescents and their families in their care.

  • Inclusion of dedicated case management services, the establishment of performance metrics, and continuous quality-improvement loops to refine processes and outcomes.

• Key Randomized Controlled Trial (RCT) evidence, though limited to only 3 trials:

  1. Asarnow et al 2005: Demonstrated that a quality-improvement intervention within PC settings led to increased therapy uptake, significant reductions in depressive symptoms, and improved quality of life for adolescents.

  2. Clarke et al 2005: Showed that integrating a brief 4-session Cognitive Behavioral Therapy (CBT) as an adjunct to SSRI medication within a collaborative care model provided a small but statistically significant additive benefit.

  3. Richardson et al 2014: Found that adolescents who chose between medication, brief CBT, or a combination within an integrative care model exhibited better 12-month response and remission rates, proving to be cost-effective as well.
     

• Despite evidence, the specific "active ingredients" contributing to the observed benefits are often unknown; these models can be resource-intensive, and guidance remains scarce for low-resource practices, posing implementation challenges.

Antidepressant Treatment Evidence

• Updated systematic review of 27 RCTs focusing on commonly prescribed selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for adolescent depression: fluoxetine, sertraline, citalopram, paroxetine, escitalopram, duloxetine, and venlafaxine.

• Older classes of antidepressants, such as tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs), were excluded from the review due to their poorer efficacy profile and/or lack of inclusion in FDA datasets for pediatric use, as well as higher side effect burden.

• Meta-analysis (Bridge et al 2005) indicated a favorable Number-needed-to-treat (NNT) to Number-needed-to-harm (NNH) ratio of $6:1$, suggesting that the clinical benefit of SSRIs generally outweighs the risk of adverse events in this population.

• Individual trial response rates, based on Clinical Global Impression-Improvement (CGI-Improvement) scores:

  • Medications: achieved response rates ranging from $47\% ext{–}69\%$ compared to placebo rates of $33\% ext{–}57\%$ (detailed in "Tables & Key Numbers").

  • Fluoxetine consistently demonstrates the most robust evidence of efficacy and is the only SSRI that is FDA-approved for use in children as young as $ext{8 yr}$ for depression.

• Treatment for Adolescents With Depression Study (TADS) (439 patients): A landmark study showing that combination therapy (fluoxetine + CBT) was superior to fluoxetine alone, which in turn was superior to CBT alone and placebo at 12 weeks; the combination therapy notably yielded a faster antidepressant response.

• Treatment of Resistant Depression in Adolescents (TORDIA) study (334 patients diagnosed with SSRI-resistant depression): Demonstrated that switching to another SSRI or venlafaxine plus adjunctive CBT significantly increased response rates (approximately $55\%$) compared to medication switch alone (approximately $41\%$), highlighting the benefit of combination approaches for treatment-resistant cases.

• Adverse events associated with antidepressants:

  • Common immediate side effects include nausea, headache, and activation (e.g., increased anxiety, agitation, insomnia, or restlessness); higher discontinuation rates were observed with duloxetine, venlafaxine, and paroxetine due to their side effect profiles.

  • Suicidality: The FDA issued a black-box warning in 2004, indicating a pooled risk of $4\%$ of emergent suicidality (including suicidal ideation and behavior, but not completed suicide) in the drug group versus $2\%$ in the placebo group in short-term trials in youth. The highest observed risk was associated with paroxetine and venlafaxine.

  • Epidemiology paradox: Despite the FDA warning, population-level suicide rates in youth have paradoxically decreased in regions where SSRI prescribing rates have increased, and toxicology reports of youth suicides rarely show the presence of antidepressants, suggesting a complex interplay of factors and the need for nuanced interpretation of the black box warning in clinical practice.

Psychotherapy Evidence

Cognitive Behavioral Therapy (CBT)

• Multiple meta-analyses consistently demonstrate the efficacy of CBT for adolescent depression; ongoing trials continue to explore its effectiveness across a broader age range, up to $ext{21 yr}$.

• In the TADS study, the CBT arm involved 15 sessions over 12 weeks and showed a response rate of $43\%$; this rate was notably not superior to placebo, potentially due to the study's focus on a severely depressed sample and the non-specific therapeutic benefits derived from regular medication visits in the placebo group.

• Computerized CBT programs (e.g., SPARX, Project "CATCH-IT") have shown effectiveness, including in PC settings, offering a scalable and accessible treatment option for some adolescents.

Interpersonal Psychotherapy for Adolescents (IPT-A)

• While fewer studies exist compared to CBT, the existing evidence for IPT-A is positive:

  • Tang et al 2009 (school-based study): Found that IPT-A was superior to treatment as usual (TAU) for reducing symptoms of depression, suicidality, and hopelessness in adolescents.

  • Baseline interpersonal problems (e.g., role disputes, grief, role transitions) have been shown to predict greater benefit from IPT-A (Gunlicks-Stoessel 2010), suggesting it is particularly effective for adolescents whose depression is intertwined with relational difficulties.

  • A skills-training variant of IPT-A proved superior to non-specific supportive counseling over an 8-week period, further supporting its targeted therapeutic approach.

Combination Therapy

• Generally recognized as superior to either single modality (medication or psychotherapy alone), especially for adolescents with moderate-to-severe depression or those who have shown resistance to initial SSRI monotherapy.

Treatment Recommendations (Evidence Grade / Consensus Strength)

• R1: PC settings should actively organize for and implement integrated/collaborative care models. (Grade 4: Strong evidence from observational studies or expert opinion, Very Strong Consensus).

  • This means establishing clear pathways for communication and coordination between PC providers, mental health specialists, and families.

• R2: For adolescents presenting with mild depression and without significant complicating factors, the initial approach should be 6–8 weeks of active support & monitoring before considering pharmacotherapy or formal psychotherapy. (Grade 3: Moderate evidence from well-designed studies, Very Strong Consensus).

  • This allows for watchful waiting, psychoeducation, and lifestyle interventions aimed at reducing symptoms.

• R3: For adolescents with moderate/severe depression or those with significant complicating factors (e.g., suicidality, comorbidity, functional impairment), immediate and proactive consultation/comanagement with a mental health specialist is crucial. Delineate clear roles and responsibilities among the care team and actively engage the family in the treatment planning process. (Grade 5: Expert opinion or consensus without explicit evidence, Strong Consensus).

• R4: PC clinicians should offer scientifically proven treatments including Cognitive Behavioral Therapy (CBT), Interpersonal Psychotherapy for Adolescents (IPT-A), and/or Selective Serotonin Reuptake Inhibitors (SSRIs). Treatment selection should be carefully tailored to the adolescent's symptom severity, individual preferences, co-occurring conditions (comorbidity), and family context. (Grade 1: Strong evidence from RCTs or systematic reviews, Very Strong Consensus).

Ongoing Management & Follow-up Recommendations

• Tracking: It is imperative to regularly assess depressive symptoms using validated scales (e.g., PHQ-A, CES-DC), monitor overall functioning across various domains (home, school, peers), and conduct ongoing assessment of suicidal risk. (Grade 4, Very Strong Consensus).

  • The ideal first follow-up visit after initiating treatment should occur within 1 week, with either a phone consultation or face-to-face meeting being acceptable, to assess initial response and address any immediate concerns.

• Monitoring of adverse events (especially emergent suicidality, activation, and induction of mania/hypomania) is absolutely mandatory throughout the course of SSRI therapy, particularly during the initial months of treatment and whenever dose adjustments are made. (Grade 3, Very Strong Consensus).

  • The FDA wording emphasizes close observation during the first months of treatment, especially considering the black box warning.

• Timeframes for reassessment and treatment duration:

  • Re-assess the diagnosis and treatment plan if no discernible improvement is observed by 6–8 weeks of initiating treatment; at this point, consider seeking an urgent mental health consult. (Grade 4, Very Strong Consensus).

  • For partial responders, comprehensively explore potential reasons for inadequate response, such as adherence issues, undiagnosed comorbidity, or ongoing psychosocial stressors; consider adding a new treatment modality or switching to an alternative, and seek mental health input. (Grade 4, Very Strong Consensus).

  • Maintenance phase: Once remission is achieved, continue antidepressant medication for at least 6–12 months to prevent relapse; monitor monthly to track stability and address any emerging concerns. The risk of the first depressive relapse is highest typically $8 ext{–}12 ext{ wk}$ post-discontinuation if medication is stopped prematurely or too abruptly.

  • For adolescents with a history of recurrent depression, maintenance treatment and monitoring should be extended for up to $ext{2 yr}$ or longer, depending on clinical judgment and risk factors.

• Shared-care: Even after a referral to a mental health specialist, the PC clinician should remain actively involved in the patient's care through a collaborative model. Collaborative or shared care models consistently demonstrate better clinical outcomes compared to fragmented care. (Grade 1, Very Strong Consensus).

Medication Dosing & Titration (SSRIs)

• General principles for prescribing SSRIs to adolescents:

  • Always start low with the initial dose to minimize side effects.

  • Titrate gradually, typically every $1 ext{–}2 ext{ wk}$, as tolerated by the patient, gradually increasing the dose until a therapeutic effect is achieved or maximum tolerated dose is reached.

  • Maximum doses in adolescents are often lower than typical adult ranges, reflecting differences in metabolism and potential sensitivity.

  • When discontinuing, taper gradually to avoid withdrawal symptoms (e.g., dizziness, nausea, paresthesia, anxiety, insomnia), which can be distressing.

• Typical dosing schedule (qd = once daily) for commonly used SSRIs:

  • Fluoxetine: Start at $10 ext{ mg qd}$ (or $5 ext{ mg}$ for children under $12$); increase by $10 ext{–}20 ext{ mg}$ increments; usual effective dose is $20 ext{ mg}$ but can go up to a maximum of $60 ext{ mg qd}$.

  • Sertraline: Start at $25 ext{ mg qd}$; increase by $12.5 ext{–}25 ext{ mg}$ increments; usual effective dose is $50 ext{ mg}$ but can go up to a maximum of $200 ext{ mg qd}$.

  • Citalopram: Start at $10 ext{ mg qd}$; increase by $10 ext{ mg}$ increments; usual effective dose is $20 ext{ mg}$ but can go up to a maximum of $60 ext{ mg qd}$.

  • Escitalopram: Start at $10 ext{ mg qd}$; increase by $5 ext{ mg}$ increments; usual effective dose is $10 ext{ mg}$ but can go up to a maximum of $20 ext{ mg qd}$.

  • Paroxetine: Start at $10 ext{ mg qd}$; usual effective dose is $20 ext{ mg}$. Caution is advised due to its association with a higher risk of suicidality and significant withdrawal symptoms; therefore, it is generally not recommended for initiation in PC settings for adolescents.

  • All SSRIs are contraindicated when used concomitantly with MAOIs due to the risk of serotonin syndrome, a potentially life-threatening condition.

CBT vs IPT-A – Core Components

• Cognitive Behavioral Therapy (CBT): A structured, short-term, present-oriented psychotherapy. Its core components include:

  • Behavioral activation: Encouraging engagement in enjoyable or meaningful activities to improve mood.

  • Cognitive restructuring: Identifying and challenging negative or distorted thought patterns that contribute to depression.

  • Problem-solving skills: Teaching systematic approaches to address life stressors.

  • Assertiveness training: Helping adolescents express their needs and boundaries effectively.

  • May include parent sessions to provide psychoeducation and support on how to support their child and manage depression-related behaviors.

• Interpersonal Psychotherapy for Adolescents (IPT-A): A time-limited psychotherapy that focuses on improving interpersonal functioning by addressing current interpersonal problems. Key components include:

  • Addressing identified interpersonal problem areas, such as grief, interpersonal role disputes, role transitions, or interpersonal deficits.

  • Improving communication patterns and fostering healthier relationships.

  • Developing interpersonal problem-solving skills to navigate social challenges.

  • Parents are typically involved in specific phases, such as the initial assessment and termination, to support the adolescent's progress and understanding of interpersonal dynamics.

Ethical, Practical, & Policy Implications

• There is a pressing need for systemic changes, including enhanced training for PC clinicians in adolescent mental health assessment and treatment, reform of reimbursement structures to adequately compensate for mental health services, and establishment of clear crisis linkages for immediate support.

• PC providers must engage in transparent discussions about the risks and benefits of various treatment options with both adolescents and their families, emphasizing shared decision-making to ensure that choices align with patient values and preferences.

• Concerns about equity arise because integrative models, while effective, can be resource-heavy and may inadvertently widen the care gap for underserved populations. The GLAD-PC guideline specifically calls for further research into the feasibility and sustainability of these models in diverse settings.

• The black-box warning on suicidality necessitates a careful balance between clinician caution and the evidence of antidepressant benefit in reducing depressive symptoms and, at a population level, potentially reducing suicide rates. Open discussion of this risk with families balanced with the overall evidence is critical.

Implementation Barriers & Future Directions

• Significant evidence gaps remain in several areas, including the efficacy of augmenting agents for treatment-resistant depression, optimal interventions for subthreshold depression, detailed understanding of the "active ingredients" or essential components of integrative models, and long-term outcomes of various treatments.

• Guidelines alone are often insufficient for widespread practice change; successful implementation requires robust dissemination strategies, ongoing quality improvement (QI) initiatives, and readily accessible tools like the GLAD-PC Toolkit (available at www.gladpc.org), which provides practical resources such as scripts, handouts, monitoring scales, and QI templates.

• Ongoing evaluation of state-level child psychiatry access programs (e.g., Project TEACH in New York, MCPAP in Massachusetts) is crucial to assess their scalability and effectiveness in bridging the mental health specialist gap for PC providers.

Tables & Key Numbers (Quick Reference)

• Prevalence in PC: Up to $ext{28}\%$ of adolescents.

• Response rates based on CGI Improvement (sample data):

  • Fluoxetine $56\%$ vs placebo $33\%$; P =.02

  • Paroxetine $66\%$ vs $48\%$; P =.02

  • Sertraline $63\%$ vs $53\%$; P =.05

• Suicidality risk (pooled data from short-term trials): $ext{SSRI}=4\%$ vs $ext{placebo}=2\%$ (representing an approximate doubling of risk, largely of ideation).

• TORDIA study for partial responders: CBT + med switch achieved a $54.8\%$ response rate (CI $47 ext{–}62\%$) vs switch alone at $40.5\%$.

Key Take-Home Messages

• For mild cases of adolescent depression, begin with active monitoring and supportive interventions; escalate treatment if no improvement is observed within 6-8 weeks.

• For moderate-to-severe depression, or when complicating factors are present, offer evidence-based treatments such as CBT/IPT-A and/or an SSRI, ideally in combination, alongside close monitoring.

• Fluoxetine continues to be the first-line SSRI choice due to extensive evidence; diligent monitoring for early activation symptoms and emergent suicidality is essential.

• Endeavor to implement integrated or collaborative care models whenever feasible within the PC setting; maintaining PC involvement is critical even if the adolescent is referred to a specialist.

• Consistently track both symptoms and overall functioning (e.g., at home, school, with peers); adjust the treatment plan promptly if an inadequate response is noted by week 6-8.

• Continue antidepressant treatment for an additional 6–12 months beyond remission to prevent relapse; for recurrent depression, monitor for $ext{1 yr}$ or longer up to $ext{2 yr}$.

• Leverage the GLAD-PC Toolkit (www.gladpc.org) for practical resources including scripts, patient handouts, validated monitoring scales, and tools to support quality improvement initiatives.